Yishai Zohar, Gelesis CEO
February 1, 2022 10:56 AM ESTUpdated 02:14 PM
Pharma
Marketing

Weight loss spin­out Gele­sis ditch­es pro­mo­tion­al staff af­ter SPAC fail — re­port

Nicole DeFeudis

Editor

As biotech stocks con­tin­ue to tum­ble, a Boston-based com­pa­ny strug­gling to gain a foothold in the noisy weight loss mar­ket is the lat­est to bring …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

A service from the Financial Times